SIREN : 534812649
APPOLON BIOTECK is a French company founded 14 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in CHAPONNAY (69970), this company of category PME shows in 2024 a revenue of 721 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 721 168 € | 1 022 748 € | 34 459 578 € | 48 674 546 € |
| Net income | -5 868 859 € | -7 823 020 € | 19 022 882 € | 14 623 185 € |
| EBITDA | -6 271 135 € | -7 632 654 € | 26 596 059 € | 20 620 916 € |
| Net margin | -813.8% | -764.9% | 55.2% | 30.0% |
In 2024, APPOLON BIOTECK achieves revenue of 721 k€. Revenue is declining over the period 2020-2024 (CAGR: -65.1%). Significant drop of -29% vs 2023. After deducting consumption (1.0 M€), gross margin stands at -288 k€, i.e. a rate of -40%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -6.3 M€, representing -869.6% of revenue. Warning negative scissor effect: despite revenue change (-29%), EBITDA varies by +18%, reducing margin by 123.3 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -5.9 M€ (-813.8% of revenue), which will impact equity.
721 168 €
-287 795 €
-6 271 135 €
-6 315 478 €
-5 868 859 €
-861.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
0.046%
93.445%
-796.061%
-0.001
50.3%
In 2024, the debt ratio of APPOLON BIOTECK (0.05) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of APPOLON BIOTECK (93.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of APPOLON BIOTECK (-0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 1083.12. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
1083.123
-0.529
In 2024, the liquidity ratio of APPOLON BIOTECK (1083.12) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of APPOLON BIOTECK (-0.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 60 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 39 days. The company must finance 21 days of gap between collections and payments. Inventory turnover is 613 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 547 days of revenue, i.e. 1.1 M€ to permanently finance. Notable WCR improvement over the period (-66%), freeing up cash.
1 096 247 €
60 j
39 j
613 j
547 j
Compare APPOLON BIOTECK with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of APPOLON BIOTECK in 2024 is 721 k€.
APPOLON BIOTECK recorded a net loss in 2024.
The headquarters of APPOLON BIOTECK is located in CHAPONNAY (69970), in the department Rhone.
The tax return of APPOLON BIOTECK is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
APPOLON BIOTECK operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.